BioAtla

BioAtla is a clinical-stage biotechnology company that researches and develops antibody therapeutics for the treatment of cancer. Read more

Jay M. Short's photo - Chairman & CEO of BioAtla

Chairman & CEO

Jay M. Short

CEO Approval Rating

78/100

Founded:

2007

Status:

PublicIndependent CompanyNASDAQBCAB

BIOATLA TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Genmab is the biggest rival of BioAtla. Genmab was founded in 1999, and its headquarters is in Copenhagen, Capital Region. Genmab operates in the Biotechnology industry. Genmab has 745 more employees than BioAtla.

NBE Therapeutics has been one of BioAtla's top competitors. NBE Therapeutics is a Private company that was founded in Basel, Basel-Country in 2012. NBE Therapeutics is in the Biotechnology industry. NBE Therapeutics has 18 more employees vs. BioAtla.

Sutro Biopharma is BioAtla's #3 rival. Sutro Biopharma was founded in 2003 in South San Francisco, California. Sutro Biopharma is in the Biotechnology field. Sutro Biopharma generates $49.8M more revenue than BioAtla.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Seattle Genetics a competitor of BioAtla?

BioAtla Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$ < 1M

BioAtla's revenue is the ranked 12th among it's top 10 competitors. The top 10 competitors average 1.1B. Over the last one quarters, BioAtla's revenue has decreased by 0%. Specifically, in Q1 2020's revenue was $ < 1M.

BioAtla Acquisitions

No recent acquisitions found related to BioAtla

BioAtla Funding History

Since BioAtla was founded in 2007, it has participated in 5 rounds of funding. In total BioAtla has raised $162.3M. BioAtla's last funding round was on Jul 2020 for a total of $72.5M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Series D
Jul 2020
$72.5M

Soleus Capital

Equity
Jan 2016
$15M
-
Debt
Jan 2016
$30M
-
Equity
Mar 2015
$39M
-
Debt
Apr 2014
$5.8M
-

Since BioAtla was founded in 2007, it has participated in 5 rounds of funding. In total BioAtla has raised $162.3M. BioAtla's last funding round was on Jul 2020 for a total of $72.5M

BioAtla Investments

No recent investments found related to BioAtla

BioAtla News

December 18, 2020BioSpace

BioAtla Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of ... See more »
December 17, 2020MarketScreener

IPOs of Bioatla and Seer boost HBM Healthcare Investments' net asset value per share

(marketscreener.com) EQS Group-News: HBM Healthcare Investments AG / Key word: IPO IPOs of Bioatla an... See more »
December 16, 2020PE Hub Network

BioAtla raises $189m for IPO

BioAtla Inc, a developer of therapeutics for treating solid tumor cancer, has raised $189 million for... See more »
December 16, 2020Nasdaq

Nasdaq Welcomes BioAtla, Inc.

Nasdaq Welcomes BioAtla, Inc.... See more »
December 15, 2020BioSpace

BioAtla Announces Pricing of Initial Public Offering

BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of ... See more »
December 12, 2020Zolmax News

BioAtla, Inc. Plans $150 Million IPO for December 16th (BCAB)

BioAtla, Inc. (BCAB) expects to raise $150 million in an IPO on Wednesday, December 16th, IPO Scoop r... See more »

BioAtla Press Releases

December 18, 2020PR Newswire

BioAtla Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

SAN DIEGO, Dec. 18, 2020 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceut... See more »
October 6, 2020Business Wire

BioAtla and BeiGene Revise Global Development and Commercialization Agreement for Novel Conditionally Active Biologic CTLA-4 Candidate BA3071

SAN DIEGO & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene will hold an exclusi... See more »
February 28, 2019PR Newswire

BioAtla Presents CAB-CTLA-4 And CAB-EpCAM-ADC Data At The American Association For Cancer Research Annual Meeting

SAN DIEGO, Feb. 27, 2019 /PRNewswire/ -- BioAtla ®, LLC, a global clinical-stage biotechnology compan... See more »
October 4, 2018PR Newswire

BioAtla Congratulates James Allison, Ph.D. For Receiving Nobel Prize

SAN DIEGO, Oct. 4, 2018 /PRNewswire/ -- BioAtla, LLC, a global biotechnology company focused on the d... See more »
June 28, 2018PR Newswire

BioAtla Announces First Patient Treated In Phase1/2 BA3021-001 Clinical Trial For CAB-ROR2-ADC Therapeutic

SAN DIEGO, June 28, 2018 /PRNewswire/ -- BioAtla, LLC, a global biotechnology company focused on the ... See more »
April 16, 2018ForImmediateRelease

Bioatla Announces FDA Clearance Of Investigational New Drug Application For CAB-ROR2-ADC Therapeutic

Travel & Tourism Industry release: SAN DIEGO, April 16, 2018 /PRNewswire/ - BioAtla, LLC, a global bi... See more »
February 28, 2018PR Newswire

BioAtla Announces First Patient Treated In Phase1/2 BA3011-001 Clinical Trial For CAB-AXL-ADC Therapeutic

SAN DIEGO, Feb. 28, 2018 /PRNewswire/ -- BioAtla, LLC, a global biotechnology company focused on the ... See more »

BioAtla Videos

Social Media

BioAtla Headquarters

11085 Torreyana Road

San Diego, California92121

1-858-558-0708

Driving Directions »

Trending Companies

BioAtla Summary

ABOUT

Overview

BioAtla is a clinical-stage biotechnology company that researches and develops antibody therapeutics for the treatment of cancer. BioAtla was founded in 2007. BioAtla's headquarters is located in San Diego, California, USA 92121. It has raised 162.3M ...

CEO

BioAtla's Chairman & CEO, Jay M. Short, currently has an approval rating of 78%. BioAtla's primary competitors are Genmab, NBE Therapeutics & Sutro Biopharma.

Frequently Asked Questions about BioAtla

  1. When was BioAtla founded?

    BioAtla was founded in 2007
  2. Who is BioAtla's CEO?

    BioAtla's CEO is Jay M. Short
  3. How much revenue does BioAtla generate?

    BioAtla generates $ < 1M in revenue
  4. How much funding does BioAtla have?

    BioAtla has historically raised $162.3M in funding
  1. Where is BioAtla's headquarters?

    BioAtla's headquarters is in San Diego California, USA
  2. How many employees does BioAtla have?

    BioAtla has 36 employees
  3. What sector does BioAtla operate in?

    BioAtla is in Biotechnology, Medical Research & Laboratories
  4. Who are BioAtla's competitors?

    BioAtla's top competitors are Genmab, NBE Therapeutics, Sutro Biopharma